A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2013
Price : $35 *
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome; Ulcerative colitis
- Focus Pharmacokinetics
- 22 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Sep 2013 New trial record